Intensive Lipid Lowering with Atorvastatin in Patients with Stable Coronary Disease

Cited by (170)

Items 101–170 of 170

1. Cardiovascular Event Reduction Versus New-Onset Diabetes During Atorvastatin Therapy
   Waters, David D., Ho, Jennifer E., Boekholdt, S. Matthijs, DeMicco, David A., Kastelein, John J.P., Messig, Michael, Breazna, Andrei, Pedersen, Terje R. · 2013 · Journal of the American College of Cardiology
2. Effect of High-Dose Atorvastatin on Hospitalizations for Heart Failure: Subgroup Analysis of the Treating to New Targets (TNT) Study
   Khush, Kiran K., Waters, David D., Bittner, Vera, Deedwania, Prakash C., Kastelein, John J.P., Lewis, Sandra J., Wenger, Nanette K. · 2007 · Circulation
3. Simvastatin Effects on Skeletal Muscle
   Larsen, Steen, Stride, Nis, Hey-Mogensen, Martin, Hansen, Christina N., Bang, Lia E., Bundgaard, Henning, Nielsen, Lars B., Helge, Jørn W., Dela, Flemming · 2013 · Journal of the American College of Cardiology
4. Statin intolerance – an attempt at a unified definition. Position paper from an International Lipid Expert Panel: This paper is also published in parallel in Archives of Medical Science [Banach M, Rizzo M, Toth PP, et al. Statin intolerance – an attempt at a unified definition. Position paper from an International Lipid Expert Panel. Arch Med Sci 2015; 11(1): 1–23]
   Banach, Maciej, Rizzo, Manfredi, Toth, Peter P, Farnier, Michel, Davidson, Michael H, Al-Rasadi, Khalid, Aronow, Wilbert S, Athyros, Vasilis, Djuric, Dragan M, Ezhov, Marat V et al. · 2015 · Expert Opinion on Drug Safety
5. The effect of statin therapy on heart failure events: a collaborative meta-analysis of unpublished data from major randomized trials
   Preiss, David, Campbell, Ross T., Murray, Heather M., Ford, Ian, Packard, Chris J., Sattar, Naveed, Rahimi, Kazem, Colhoun, Helen M., Waters, David D., LaRosa, John C. et al. · 2015 · European Heart Journal
6. Effect of statins on atrial fibrillation: collaborative meta-analysis of published and unpublished evidence from randomised controlled trials
   Rahimi, K., Emberson, J., McGale, P., Majoni, W., Merhi, A., Asselbergs, F. W., Krane, V., Macfarlane, P. W., PWM is acting on behalf of the PROSPER Executive · 2011 · BMJ
7. Non–High-Density Lipoprotein Cholesterol Versus Apolipoprotein B in Cardiovascular Risk Stratification
   Ramjee, Vimal, Sperling, Laurence S., Jacobson, Terry A. · 2011 · Journal of the American College of Cardiology
8. Plasma triglycerides and cardiovascular events in the Treating to New Targets and Incremental Decrease in End-Points through Aggressive Lipid Lowering trials of statins in patients with coronary artery disease
   Faergeman, Ole, Holme, Ingar, Fayyad, Rana, Bhatia, Sonal, Grundy, Scott M., Kastelein, John J.P., LaRosa, John C., Larsen, Mogens Lytken, Lindahl, Christina, Olsson, Anders G. et al. · 2009 · The American Journal of Cardiology
9. Managing the residual cardiovascular disease risk associated with HDL-cholesterol and triglycerides in statin-treated patients: A clinical update
   Reiner, Ž. · 2013 · Nutrition, Metabolism and Cardiovascular Diseases
10. Blood Pressure and Cholesterol Control in Hypertensive Hypercholesterolemic Patients: National Health and Nutrition Examination Surveys 1988–2010
    Egan, Brent M., Li, Jiexiang, Qanungo, Suparna, Wolfman, Tamara E. · 2013 · Circulation
11. Outcomes of using high- or low-dose atorvastatin in patients 65 years of age or older with stable coronary heart disease
    Wenger, Nanette K., Lewis, Sandra J., Herrington, David M., Bittner, Vera, Welty, Francine K., for the Treating to New Targets Study Steering Committee and Investigators · 2007 · Annals of Internal Medicine
12. Beyond Low-Density Lipoprotein Cholesterol
    Mudd, James O., Borlaug, Barry A., Johnston, Peter V., Kral, Brian G., Rouf, Rosanne, Blumenthal, Roger S., Kwiterovich, Peter O. · 2007 · Journal of the American College of Cardiology
13. Stabilizing effect of combined eicosapentaenoic acid and statin therapy on coronary thin-cap fibroatheroma
    Nishio, Ryo, Shinke, Toshiro, Otake, Hiromasa, Nakagawa, Masayuki, Nagoshi, Ryoji, Inoue, Takumi, Kozuki, Amane, Hariki, Hirotoshi, Osue, Tsuyoshi, Taniguchi, Yu et al. · 2014 · Atherosclerosis
14. National lipid association annual summary of clinical lipidology 2016
    Bays, Harold E., Jones, Peter H., Orringer, Carl E., Brown, W. Virgil, Jacobson, Terry A. · 2016 · Journal of Clinical Lipidology
15. Reductions in Atherogenic Lipids and Major Cardiovascular Events: A Pooled Analysis of 10 ODYSSEY Trials Comparing Alirocumab With Control
    Ray, Kausik K., Ginsberg, Henry N., Davidson, Michael H., Pordy, Robert, Bessac, Laurence, Minini, Pascal, Eckel, Robert H., Cannon, Christopher P. · 2016 · Circulation
16. 2026 ACC/AHA/AACVPR/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Dyslipidemia: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines
    Writing Committee Members, Blumenthal, Roger S., Morris, Pamela B., Gaudino, Mario, Johnson, Heather M., Anderson, Timothy S., Bittner, Vera A., Blankstein, Ron, Brewer, LaPrincess C., Cho, Leslie et al. · 2026 · Circulation
17. Apolipoproteins as markers and managers of coronary risk
    Chan, D.C. · 2006 · QJM
18. Introducing the ‘Drucebo’ effect in statin therapy: a systematic review of studies comparing reported rates of statin‐associated muscle symptoms, under blinded and open‐label conditions
    Penson, Peter E., Mancini, G. B. John, Toth, Peter P., Martin, Seth S., Watts, Gerald F., Sahebkar, Amirhossein, Mikhailidis, Dimitri P., Banach, Maciej, on behalf of Lipid and Blood Pressure Meta‐Analysis Collaboration (LBPMC) Group & International Lipid Expert Panel (ILEP) · 2018 · Journal of Cachexia, Sarcopenia and Muscle
19. Evolution of the Lipid Trial Protocol of the Action to Control Cardiovascular Risk in Diabetes (ACCORD) Trial
    Ginsberg, Henry N., Bonds, Denise E., Lovato, Laura C., Crouse, John R., Elam, Marshall B., Linz, Peter E., O’Connor, Patrick J., Leiter, Lawrence A., Weiss, Daniel, Lipkin, Edward et al. · 2007 · The American Journal of Cardiology
20. Inclisiran: a new promising agent in the management of hypercholesterolemia
    Kosmas, Constantine E., Muñoz Estrella, Alba, Sourlas, Andreas, Silverio, Delia, Hilario, Elizabeth, Montan, Peter D., Guzman, Eliscer · 2018 · Diseases
21. Prevalence, Predictors, and Outcomes in Treatment-resistant Hypertension in Patients with Coronary Disease
    Bangalore, Sripal, Fayyad, Rana, Laskey, Rachel, DeMicco, David A., Deedwania, Prakash, Kostis, John B., Messerli, Franz H. · 2014 · The American Journal of Medicine
22. Evidence-based goals in LDL-C reduction
    Soran, Handrean, Dent, Ricardo, Durrington, Paul · 2017 · Clinical Research in Cardiology
23. Safety and efficacy of ezetimibe: A meta-analysis
    Savarese, Gianluigi, De Ferrari, Gaetano M., Rosano, Giuseppe M.C., Perrone-Filardi, Pasquale · 2015 · International Journal of Cardiology
24. Nicotinic acid, alone and in combinations, for reduction of cardiovascular risk
    Brown, B. Greg, Zhao, Xue-Qiao · 2008 · The American Journal of Cardiology
25. Lipid-lowering therapy use in primary and secondary care in Central and Eastern Europe: DA VINCI observational study
    Vrablik, Michal, Seifert, Bohumil, Parkhomenko, Alexander, Banach, Maciej, Jóźwiak, Jacek J., Kiss, Robert Gabor, Gaita, Dan, Rašlová, Katarina, Zachlederova, Marie, Bray, Sarah et al. · 2021 · Atherosclerosis
26. Effect of intensive lipid-lowering therapy on mortality after acute coronary syndrome (a patient-level analysis of the Aggrastat to Zocor and Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 trials)
    Murphy, Sabina A., Cannon, Christopher P., Wiviott, Stephen D., de Lemos, James A., Blazing, Michael A., McCabe, Carolyn H., Califf, Robert M., Braunwald, Eugene · 2007 · The American Journal of Cardiology
27. Statin Use and Adverse Effects Among Adults >75 Years of Age: Insights From the Patient and Provider Assessment of Lipid Management (PALM) Registry
    Nanna, Michael G., Navar, Ann Marie, Wang, Tracy Y., Mi, Xiaojuan, Virani, Salim S., Louie, Michael J., Lee, L. Veronica, Goldberg, Anne C., Roger, Veronique L., Robinson, Jennifer et al. · 2018 · Journal of the American Heart Association
28. Statins: an essential component in the management of carotid artery disease
    Paraskevas, Kosmas I., Hamilton, George, Mikhailidis, Dimitri P. · 2007 · Journal of Vascular Surgery
29. Pleiotropic Effects of Statins: Evidence Against Benefits Beyond LDL-Cholesterol Lowering
    Pedersen, Terje R. · 2010 · American Journal Cardiovascular Drugs
30. Association of lowering low-density lipoprotein cholesterol with contemporary lipid-lowering therapies and risk of diabetes mellitus: a systematic review and meta-analysis
    Khan, Safi U., Rahman, Hammad, Okunrintemi, Victor, Riaz, Haris, Khan, Muhammad Shahzeb, Sattur, Sudhakar, Kaluski, Edo, Lincoff, A. Michael, Martin, Seth S., Blaha, Michael J. · 2019 · Journal of the American Heart Association
31. Association of lowering apolipoprotein B with cardiovascular outcomes across various lipid-lowering therapies: systematic review and meta-analysis of trials
    Khan, Safi U, Khan, Muhammad U, Valavoor, Shahul, Khan, Muhammad Shahzeb, Okunrintemi, Victor, Mamas, Mamas A, Leucker, Thorsten M, Blaha, Michael J, Michos, Erin D · 2020 · European Journal of Preventive Cardiology
32. Dyslipidemia
    Mancini, G.B. John, Hegele, Robert A., Leiter, Lawrence A. · 2018 · Canadian Journal of Diabetes
33. Dyslipidaemia in the metabolic syndrome and type 2 diabetes: Pathogenesis, priorities, pharmacotherapies
    Chan, Dick C, Watts, Gerald F · 2011 · Expert Opinion on Pharmacotherapy
34. Low density lipoprotein cholesterol, statins and cardiovascular events: a meta-analysis
    Genser, Bernd, März, Winfried · 2006 · Clinical Research in Cardiology
35. Statins and C‐Reactive Protein Levels
    Asher, Jordan, Houston, Mark · 2007 · The Journal of Clinical Hypertension
36. The metabolic syndrome and endothelial dysfunction: Common highway to type 2 diabetes and CVD?
    Diamant, Michaela, Tushuizen, Maarten E. · 2006 · Current Diabetes Reports
37. Impact of Smoking on Cardiovascular Events in Patients With Coronary Disease Receiving Contemporary Medical Therapy (from the Treating to New Targets [TNT] and the Incremental Decrease in End Points Through Aggressive Lipid Lowering [IDEAL] Trials)
    Frey, Paul, Waters, David D., DeMicco, David A., Breazna, Andrei, Samuels, Larry, Pipe, Andrew, Wun, Chuan-Chuan, Benowitz, Neal L. · 2011 · The American Journal of Cardiology
38. Diabetes and Cardiovascular Disease Prevention in Older Adults
    Cigolle, Christine T., Blaum, Caroline S., Halter, Jeffrey B. · 2009 · Clinics in Geriatric Medicine
39. Update on the laboratory investigation of dyslipidemias
    Ramasamy, I. · 2018 · Clinica Chimica Acta
40. 2013 Cholesterol Guidelines Revisited: Percent LDL Cholesterol Reduction or Attained LDL Cholesterol Level or Both for Prognosis?
    Bangalore, Sripal, Fayyad, Rana, Kastelein, John J., Laskey, Rachel, Amarenco, Pierre, DeMicco, David A., Waters, David D. · 2016 · The American Journal of Medicine
41. Intensity of Statin Therapy, Achieved Low-Density Lipoprotein Cholesterol Levels and Cardiovascular Outcomes in Japanese Patients After Coronary Revascularization: – Perspectives From the CREDO-Kyoto Registry Cohort-2 –
    Natsuaki, Masahiro, Furukawa, Yutaka, Morimoto, Takeshi, Nakagawa, Yoshihisa, Ono, Koh, Kaburagi, Satoshi, Inada, Tsukasa, Mitsuoka, Hirokazu, Taniguchi, Ryoji, Nakano, Akira et al. · 2012 · Circulation Journal
42. Use of Lipid-modifying Therapy and LDL-C Goal Attainment in a High-Cardiovascular-Risk Population in the Netherlands
    Kuiper, Josephina G., Sanchez, Robert J., Houben, Eline, Heintjes, Edith M., Penning-van Beest, Fernie J.A., Khan, Irfan, van Riemsdijk, Melanie, Herings, Ron M.C. · 2017 · Clinical Therapeutics
43. Alirocumab after acute coronary syndrome in patients with a history of heart failure
    White, Harvey D, Schwartz, Gregory G, Szarek, Michael, Bhatt, Deepak L, Bittner, Vera A, Chiang, Chern-En, Diaz, Rafael, Goodman, Shaun G, Jukema, Johan Wouter, Loy, Megan et al. · 2022 · European Heart Journal
44. The epidemiological concept of residual risk
    Vanuzzo, Diego · 2011 · Internal and Emergency Medicine
45. Treating mixed hyperlipidemia and the atherogenic lipid phenotype for prevention of cardiovascular events
    Rubenfire, Melvyn, Brook, Robert D., Rosenson, Robert S. · 2010 · The American Journal of Medicine
46. Association between weight change and incidence of cardiovascular disease events and mortality among adults with type 2 diabetes: a systematic review of observational studies and behavioural intervention trials
    Strelitz, Jean, Lawlor, Emma R., Wu, Yue, Estlin, Annabel, Nandakumar, Giri, Ahern, Amy L., Griffin, Simon J. · 2022 · Diabetologia
47. Beyond LDL-C: unravelling the residual atherosclerotic cardiovascular disease risk landscape—focus on hypertriglyceridaemia
    Bashir, Bilal, Schofield, Jonathan, Downie, Paul, France, Michael, Ashcroft, Darren M., Wright, Alison K., Romeo, Stefano, Gouni-Berthold, Ioanna, Maan, Akhlaq, Durrington, Paul N. et al. · 2024 · Frontiers in Cardiovascular Medicine
48. Very low LDL-C levels may safely provide additional clinical cardiovascular benefit: the evidence to date
    McCormack, Terry, Dent, Ricardo, Blagden, Mark · 2016 · International Journal of Clinical Practice
49. Apolipoprotein profiling as a personalized approach to the diagnosis and treatment of dyslipidaemia
    Renee Ruhaak, L, van der Laarse, Arnoud, Cobbaert, Christa M · 2019 · Annals of Clinical Biochemistry: International Journal of Laboratory Medicine
50. Impact of high-dose atorvastatin therapy and clinical risk factors on incident aortic valve stenosis in patients with cardiovascular disease (from TNT, IDEAL, and SPARCL)
    Arsenault, Benoit J., Boekholdt, S. Matthijs, Mora, Samia, DeMicco, David A., Bao, Weihang, Tardif, Jean-Claude, Amarenco, Pierre, Pedersen, Terje, Barter, Philip, Waters, David D. · 2014 · The American Journal of Cardiology
51. Relationship between Coronary Artery Disease and Non-HDL-C, and Effect of Highly Purified EPA on the Risk of Coronary Artery Disease in Hypercholesterolemic Patients Treated with Statins: Sub-Analysis of the Japan EPA Lipid Intervention Study (JELIS)
    Sasaki, Jun, Yokoyama, Mitsuhiro, Matsuzaki, Masunori, Saito, Yasushi, Origasa, Hideki, Ishikawa, Yuichi, Oikawa, Shinichi, Itakura, Hiroshige, Hishida, Hitoshi, Kita, Toru et al. · 2012 · Journal of Atherosclerosis and Thrombosis
52. Unmet needs in the diagnosis and treatment of dyslipidemia in the primary care setting in Germany
    Böhler, S., Scharnagl, H., Freisinger, F., Stojakovic, T., Glaesmer, H., Klotsche, J., Pieper, L., Pittrow, D., Kirch, W., Schneider, H. et al. · 2007 · Atherosclerosis
53. Prescription Omega-3 Fatty Acid as an Adjunct to Fenofibrate Therapy in Hypertriglyceridemic Subjects
    Roth, Eli M, Bays, Harold E, Forker, Alan D, Maki, Kevin C, Carter, Roderick, Doyle, Ralph T, Stein, Evan A · 2009 · Journal of Cardiovascular Pharmacology
54. Risk factors for stroke and lipid-lowering effect of pravastatin on the risk of stroke in Japanese patients with hypercholesterolemia: Analysis of data from the MEGA Study, a large randomized controlled trial
    Uchiyama, Shinichiro, Nakaya, Noriaki, Mizuno, Kyoichi, Ohashi, Yasuo, Tajima, Naoko, Kushiro, Toshio, Teramoto, Tamio, Nakamura, Haruo · 2009 · Journal of the Neurological Sciences
55. HDL Hypothesis: Where Do We Stand Now?
    Tariq, Sayed M., Sidhu, Mandeep S., Toth, Peter P., Boden, William E. · 2014 · Current Atherosclerosis Reports
56. Non‐<scp>HDL</scp> cholesterol vs. Apo B for risk of coronary heart disease in healthy individuals: the <scp>EPIC</scp>‐Norfolk prospective population study
    Sondermeijer, Brigitte M., Rana, Jamal S., Arsenault, Benoit J., Shah, Prediman K., Kastelein, John J.P., Wareham, Nicholas J., Boekholdt, S. Matthijs, Khaw, Kay‐Tee · 2013 · European Journal of Clinical Investigation
57. Malondialdehyde-modified low-density lipoprotein is a predictor of cardiac events in patients with stable angina on lipid-lowering therapy after percutaneous coronary intervention using drug-eluting stent
    Ito, Tsuyoshi, Fujita, Hiroshi, Tani, Tomomitsu, Ohte, Nobuyuki · 2015 · Atherosclerosis
58. Cost-effectiveness of statins in the prevention of coronary heart disease events in middle-aged Finnish men
    Peura, Piia, Martikainen, Janne, Soini, Erkki, Hallinen, Taru, Niskanen, Leo · 2008 · Current Medical Research and Opinion
59. A prospective study of statin use and mortality among 67,385 blacks and whites in the Southeastern United States
    Lipworth, Loren, Fazio, Sergio, Kabagambe, Edmond, Munro, Heather, Nwazue, Victor, Tarone, Robert, McLaughlin, Joseph, Blot, William, Sampson, Uchechukwu · 2013 · Clinical Epidemiology
60. Relation of intensity of statin therapy and outcomes after transcatheter aortic valve replacement
    Huded, Chetan P., Benck, Lillian R., Stone, Neil J., Sweis, Ranya N., Ricciardi, Mark J., Malaisrie, S. Chris, Davidson, Charles J., Flaherty, James D. · 2017 · The American Journal of Cardiology
61. GetReal in mathematical modelling: a review of studies predicting drug effectiveness in the real world.
    Panayidou, Klea, Gsteiger, Sandro, Egger, Matthias, Kilcher, Gablu, Carreras, Máximo, Efthimiou, Orestis, Debray, Thomas P. A., Trelle, Sven, Hummel, Noemi, on behalf of the GetReal methods review group · 2016 · Research Synthesis Methods
62. Lowering LDL cholesterol in adults: a prospective, community-based practice initiative
    Coodley, Gregg O., Jorgensen, Maryclair, Kirschenbaum, Jack, Sparks, Chieko, Zeigler, Lisa, Albertson, Barry D. · 2008 · The American Journal of Medicine
63. Quantifying Unmet Need in Statin-Treated Hyperlipidemia Patients and the Potential Benefit of Further LDL-C Reduction Through an EHR-Based Retrospective Cohort Study
    Schleyer, Titus, Hui, Siu, Wang, Jane, Zhang, Zuoyi, Knapp, Kristina, Baker, Jarod, Chase, Monica, Boggs, Robert, Simpson, Ross J. · 2019 · Journal of Managed Care &amp; Specialty Pharmacy
64. Substituting non-HDL cholesterol with LDL as a guide for lipid-lowering therapy increases the number of patients with indication for therapy
    Masana, Luís, Ibarretxe, Daiana, Heras, Mercedes, Cabré, Anna, Ferré, Raimon, Merino, Jordi, Plana, Núria, Girona, Josefa · 2013 · Atherosclerosis
65. Safety and efficacy of antisense oligonucleotides on triglyceride, apolipoprotein C-III, and other lipid parameters levels in hypertriglyceridemia; a network meta-analysis of randomized controlled trials
    Mahmoud, Abdelrahman, Abdelsayed, Kerollos, Mohamed, Ahmed Almahdy, Najah, Qasi, Abdulkader, Anas, Ali, Karim, Tabassum, Shehroze, Abouzid, Mohamed Riad, Abdelazeem, Basel, Mills, James D. · 2025 · Lipids in Health and Disease
66. The Impact of Pravastatin Therapy on Long-Term Outcome in Patients With Metabolic Syndrome Undergoing Complete Coronary Revascularization
    Kasai, Takatoshi, Miyauchi, Katsumi, Kajimoto, Kan, Kubota, Naozumi, Kurata, Takeshi, Amano, Atsushi, Daida, Hiroyuki · 2009 · Circulation Journal
67. On-treatment lipoprotein components and risk of cerebrovascular events in the Treating to New Targets study
    van den Bogaard, Bas, van den Born, Bert-Jan H., Fayyad, Rana, Waters, David D., DeMicco, David A., LaRosa, John C., Kastelein, John J. P., Holme, Ingar, On behalf of the Treating to New Targets investigators · 2011 · European Journal of Clinical Investigation
68. The Relationship Between Low-Density Lipoprotein Cholesterol Levels and the Incidence of Cardiovascular Disease in High-Risk Patients Treated With Pravastatin: Main Results of the APPROACH-J Study
    Daida, Hiroyuki, Teramoto, Tamio, Kitagawa, Yasuhisa, Matsushita, Yasuyuki, Sugihara, Masahiro, APPROACH-J Study Group · 2014 · International Heart Journal
69. Addition of Bempedoic Acid to Statin–Ezetimibe versus Statin Titration in Patients with High Cardiovascular Risk: A Single-Centre Prospective Study
    Marazzi, Giuseppe, Caminiti, Giuseppe, Perrone, Marco, Campolongo, Giuseppe, Cacciotti, Luca, Giamundo, Domenico, Iellamo, Ferdinando, Severino, Paolo, Volterrani, Maurizio, Rosano, Giuseppe · 2024 · Journal of Cardiovascular Development and Disease
70. Impact of the statin escape phenomenon on long-term clinical outcomes in patients with acute myocardial infarction: Subgroup analysis of the Nagoya Acute Myocardial Infarction Study (NAMIS)
    Ota, Tomoyuki, Ishii, Hideki, Suzuki, Susumu, Shibata, Yohei, Tatami, Yosuke, Harata, Shingo, Shimbo, Yusaku, Takayama, Yohei, Tanaka, Akihito, Kawamura, Yoshihiro et al. · 2015 · Atherosclerosis